Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 29-37 , January 2006

Novel Radiation-Enhancing Agents in Malignant Gliomas

  • Min Zhang, MD, PhD
    • ,
  • Arnab Chakravarti, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Arnab Chakravarti, MD, Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, 100 Blossom Street Cox 3, Boston, MA 02114

References 

  1. Stupp R , Mason WP , van den Bent MJ , et al.   Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma . N Engl J Med . 2005;352:987–996
  2. Walker MD , Alexander E , Hunt WE . Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas . J Neurosurg . 1978;49:333–343
  3. Walker MD , Green SB , Byar DP . Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant gliomas after surgery . N Engl J Med . 1980;303:1323–1329
  4. Maher EA , Furnari FB , Bachoo RM , et al.   Malignant glioma (Genetics and biology of a grave matter) . Genes Dev . 2001;15:1311–1333
  5. Fine H , Dear KB , Loeffler JS , et al.   Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults . Cancer . 1993;71:2585–2597
  6. Stewart LA . Chemotherapy in adult high-grade glioma (A systematic review and meta-analysis of individual patient data from 12 randomised trials) . Lancet . 2002;359:1011–1018
  7. Party MRCBTW . Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma (A Medical Research Council trial) . J Clin Oncol . 2001;19:509–518
  8. Newlands ES , Stevens MF , Wedge SR , et al.   Temozolomide (A review of its discovery, chemical properties, pre-clinical development, and clinical trials) . Cancer Treat Rev . 1997;23:35–61
  9. Wedge SR , Porteous JK , Glaser MG , et al.   In vitro evaluation of temozolomide combined with X-irradiation . Anticancer Drugs . 1997;8:92–97
  10. Newlands ES , Blackledge G , Slack RS . Phase I trial of temozolomide (CCRG 81045: M&B 39831:NSC 362856) . Br J Cancer . 1992;65:287–291
  11. Yung WK , Albright RE , Olson J , et al.   A phase II study of temozolomide vs. procarbazine in patients with glioblastoma at first relapse . Br J Cancer . 2000;83:588–593
  12. Stupp R , Dietrich PY , Ostermann KS , et al.   Promising survival for patients with newly-diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide . J Clin Oncol . 2002;20:1375–1382
  13. Hegi ME , Diserens AC , Gorlia T , et al.   MGMT gene silencing and benefit from temozolomide in glioblastoma . N Engl J Med . 2005;352:997–1003
  14. Hackel PO , Zwick E , Prenzel N , et al.   Epidermal growth factor receptors (Critical mediators of multiple receptor pathways) . Curr Opin Cell Biol . 1999;11:184–189
  15. Woodburn JR . The epidermal growth factor receptor and its inhibition in cancer therapy . Pharmacol. Ther . 1999;82:241–250
  16. Zwick E , Hackel PO , Prenzel N , et al.   The EGF receptor as central transducer of heterologous signalling systems . Trends Pharmacol Sci . 1999;20:408–412
  17. Ang K , Berkey BA , Tu X , et al.   Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma . Cancer Res . 2002;62:7350–7356
  18. Baselga J , Albanell J . Targeting epidermal growth factor receptor in lung cancer . Curr Oncol Rep . 2002;4:317–324
  19. Baselga J . Why the epidermal growth factor receptor? The rationale for cancer therapy . Oncologist . 2002;7(suppl 4):2–8
  20. Balaban N , Moni J , Shannon M , et al.   The effect of ionizing radiation on signal transduction (Antibodies to EGF receptor sensitize A431 cells to radiation) . Biochim Biophys Acta . 1996;1314:147–156
  21. Chakravarti A , Dicker A , Mehta M . The contribution of EGFR signaling in human gliomas (A review of preclinical and correlative data) . Int J Radiat Oncol Biol Phys . 2004;58:927–931
  22. Chakravarti A , Loeffler JS , Dyson NJ . Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through the continued activation of phosphoinositide 3-kinase signaling . Cancer Res . 2002;62:200–207
  23. Chakravarti A , Chakladar A , Delaney MA , et al.   The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a ras-dependent manner . Cancer Res . 2002;62:4307–4315
  24. Ciardiello F , Bianco R , Damiano V , et al.   Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells . Clin Cancer Res . 2000;6:3739–3747
  25. Ciardiello F . Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents . Drugs . 2000;60(suppl 1):25–32 discussion 41-42
  26. Dent P , Reardon DB , Park JS , et al.   Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death . Mol Biol Cell . 1999;10:2493–2506
  27. Barker FG , Simmons ML , Chang SM , et al.   EGFR overexpression and radiation response in glioblastoma multiforme . Int J Radiat Oncol Biol Phys . 2001;51:410–418
  28. Shinojima N , Tada K , Shiraishi S , et al.   Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme . Cancer Res . 2003;63:6962–6970
  29. Chakravarti A , Delaney MA , Noll E , et al.   Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas . Clin Cancer Res . 2001;7:2387–2395
  30. Etienne M-C , Formento JL , Lebrun-Frenay C , et al.   Epidermal growth factor receptor and labeling index are independent prognostic factors in glial turmor outcome . Clin Cancer Res . 1998;4:2383–2390
  31. Feldkamp MM , Lala P , Lau N , et al.   Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens . Neurosurgery . 1999;45:1442–1453
  32. Smith JS , Tachibana I , Passe SM , et al.   PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme . J Nat Cancer Inst . 2001;93:1246–1256
  33. Rainov NG , Dobberstein KU , Bahn H . Prognostic factors in malignant glioma (Influence of the overexpression of oncogene and tumor-suppressor gene products on survival) . J Neurooncol . 1997;35:13–28
  34. Chakravarti A , Seiferheld W , Tu X , et al.   Immunohistochemically determined total EGFR levels are not of prognostic value in newly diagnosed GBM (A report from the Radiation Therapy Oncology Group) . Int J Radiat Oncol Biol Phys . 2005;62:318–327
  35. Buckner JC . Immunohistochemical detection of EGFRvIII and prognostic significance in patinets with malignant glioma enrolled in NCCTG clinical trials . J Clin Oncol . 2004;22:1508
  36. Prados M . Phase I study of ZD1839 plus temozolomide in patients with malignant glioma . J Clin Oncol . 2004;22:1504
  37. Rich J , Reardon DA , Peery T , et al.   Phase II trial of gefitinib in recurrent glioblastoma . J Clin Oncol . 2004;22:133–142
  38. Prados M . Phase I study of OSI-774 alone or with temozolamide in patients with malignant glioma . Proc Am Soc Clin Oncol . 2003;22:99
  39. Raizer JJ . A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas not on EIACDs . J Clin Oncol . 2004;22:1502
  40. Chakravarti A , Zhai G , Suzuki Y , et al.   The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas . J Clin Oncol . 2004;22:1926–1933
  41. Chakravarti A , Loeffler JS , Dyson NJ . Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of physphoinositide 3-kinase signaling . Cancer Res . 2002;62:200–207
  42. Chakravarti A . An update of phase I data from RTOG 0211 (A phase I/II clinical study of gefitinib+radiation for newly-diagnosed GBM patients) . J Clin Oncol . 2004;22:1571
  43. Galanis E . NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM) . J Clin Oncol . 2004;22:1503
  44. Conrad C . A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent GBM . J Clin Oncol . 2004;22:1512
  45. Reardon DA . A phase I/II trial of PTK-787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent GBM . J Clin Oncol . 2004;22:1513

PII: S1053-4296(05)00048-2

doi: 10.1016/j.semradonc.2005.08.004

Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 29-37 , January 2006

Article Tools

* Image Usage & Resolution